Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Xenon (XENE)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Evolus (EOLS – Research Report) and Xenon (XENE – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Evolus (EOLS)
In a report issued on January 9, Serge Belanger from Needham maintained a Hold rating on Evolus. The company’s shares closed last Friday at $5.65.
According to TipRanks.com, Belanger is a 5-star analyst with an average return of
Currently, the analyst consensus on Evolus is a Strong Buy with an average price target of $19.25.
See the top stocks recommended by analysts >>
Xenon (XENE)
Goldman Sachs analyst Paul Choi reiterated a Buy rating on Xenon on January 9. The company’s shares closed last Friday at $42.15.
According to TipRanks.com, Choi is a 4-star analyst with an average return of
Xenon has an analyst consensus of Strong Buy, with a price target consensus of $54.09, implying a 30.2% upside from current levels. In a report issued on December 31, Chardan Capital also initiated coverage with a Buy rating on the stock with a $55.00 price target.
